BrianLeeMcCluneDO
Oncology • Salt Lake City, UTHematologic Oncology
Associate Professor, Medicine, University of Utah
Dr. McClune is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1950 Circle of Hope Dr
Salt Lake City, UT 84112Phone+1 801-585-0100
Education & Training
University of TennesseeFellowship, Hematology and Medical Oncology, 2003 - 2006
Johns Hopkins UniversityResidency, Internal Medicine, 2000 - 2003
Kansas City University of Medicine and Biosciences College of Osteopathic MedicineClass of 2000
Certifications & Licensure
UT State License 2019 - 2026
KS State License 2018 - 2020
MN State License 2006 - 2018
TN State License 2003 - 2011- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Autologous Transplant for Multiple Myeloma Start of enrollment: 2004 Apr 20
- Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403) Start of enrollment: 2007 Aug 01
- Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors Start of enrollment: 2006 Dec 19
- Join now to see all
Publications & Presentations
PubMed
- 844 citationsLenalidomide after stem-cell transplantation for multiple myelomaPhilip L. McCarthy, Kouros Owzar, Craig C. Hofmeister, David D. Hurd, Hani Hassoun
The New England Journal of Medicine. 2012-05-09 - 23 citationsInfection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019.Nicole Balmaceda, Muhammad Aziz, Viveksandeep Thoguluva Chandrasekar, Brian McClune, Suman Kambhampati
BMC Cancer. 2021-06-26 - 9 citationsHospitalization at the end of life in patients with multiple myeloma.Saqib Abbasi, John Roller, Al-Ola Abdallah, Leyla Shune, Brian McClune
BMC Cancer. 2021-03-31
Journal Articles
- Caution with Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple MyelomaBrian McClune, DO, JAMA Oncology
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
